Evaluating patient perceptions of telemedicine quality in neuro-oncology

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study assesses how patients with central nervous system cancers perceive the quality of care they receive through telemedicine compared to in-person visits. It involves administering surveys to patients and reviewing their medical charts to gather data on various aspects of care delivery. The study aims to characterize differences in visit types, time spent, and the frequency of acute care sought after telemedicine encounters. By understanding these perceptions, the study seeks to improve telemedicine practices in neuro-oncology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a CNS tumors: this includes patients with primary brain tumors, brain metastases, and leptomeningeal disease
* Established patients with a follow up encounter with Neuro-Oncology at the Brain and Spine Center at the University of Texas MD Anderson Cancer Center; this encounter can be

  * An in-person visit
  * A telemedicine appointment

Exclusion Criteria:

* Encounter occurred with the assistance of official language translation support
* Patients with telephone encounters (without interactive video)
* New patient or consult visits
* Neither patient nor caregiver present during the visit are available or able to answer survey questions

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Barbara J O'Brien, MD — M.D. Anderson Cancer Center
• Study coordinator: Barbara J O'Brien, MD
• Email: bjobrien@mdanderson.org
• Phone: 713-794-4380

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using gadolinium and ferumoxytol MRI to diagnose central nervous system abnormalities

  This study is testing if using two different MRI contrast agents, gadolinium and ferumoxytol, can help better diagnose problems in the central nervous system for patients with suspected abnormalities.

  Recruiting Phase 2 OHSU Knight Cancer Institute · Portland, Oregon · NCT03270059

• 64Cu-DOTA-Pembrolizumab PET to See If Treatment Is Working in Stage IV NSCLC

  This study tests a new PET imaging agent paired with pembrolizumab to see if it can show which tumors are still responding in adults with stage IV NSCLC who are already receiving pembrolizumab.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07619599

• Advanced MRI to distinguish recurrent brain tumor from radiation necrosis

  This trial tests whether advanced MRI scans (DR-CSI and sodium imaging) can tell if people with metastatic brain tumors have tumor recurrence or treatment-related radiation necrosis.

  Recruiting Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07339085

• Exercise Together for patients with primary brain tumors and their caregivers

  A supervised, partner-based exercise program is being tested to see if it’s safe and helps patients with primary brain tumors and their caregivers feel better and function more easily.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT07278440

• Virtual exercise program to help brain tumor survivors with cognitive issues

  This study is testing a virtual exercise program to see if it can help brain tumor survivors improve their thinking skills and get more active.

  Recruiting at 2 sites Emory University · Atlanta, Georgia and 1 other locations · NCT06799481

• Imaging brain tumors using a targeted radioimmunoconjugate and PET scans

  This study is testing a new imaging method using a special drug to see if it can help identify immune cells in patients with brain tumors before they have surgery.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT06650163

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.